Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access
Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc
Journal website https://gr.elmerpub.com

Short Communication

Volume 19, Number 2, April 2026, pages 110-117

Socioeconomic Deprivation Does Not Influence Disease Severity or Access to Dupilumab in Eosinophilic Esophagitis

Figures

↓  Figure 1. No correlation was found between ADI and eosinophil count in proximal esophagus (a) and distal esophagus (b). ADI: Area Deprivation Index.
Figure 1.
↓  Figure 2. In addition to patients who responded to non-dupilumab therapies (a), a subset of refractory patients (b) demonstrated significant histological improvement with dupilumab (*P value < 0.05).
Figure 2.
↓  Figure 3. No difference was found in ADI (a) and eosinophil count in distal and proximal esophagus (b) between the overall cohort and dupilumab-treated patients. ADI: Area Deprivation Index.
Figure 3.

Tables

↓  Table 1. Patient Demographics and ADI Distribution
 
ADI: Area Deprivation Index; SD: standard deviation.
Age at diagnosis (1–18 years), mean ± SD8.6 ± 5.05
Sex
  Male68%
  Female32%
Race
  White73%
  Black22%
  Hispanic3%
ADI distribution
  1–342%
  4–726%
  8–1032%

 

↓  Table 2. Demographic Characteristics of Patients Who Responded to Conventional Therapies
 
SD: standard deviation; HPF: high power field; PPI: proton pump inhibitor; STC: swallowed topical corticosteroid.
Age at diagnosis (1–18 years), mean ± SD8.56 ± 5.13
Sex, n (%)
  Male89 (69%)
  Female40 (31%)
Race
  White74%
  Black22%
  Hispanic2%
Baseline eosinophil count/HPF
  Distal esophagus41.7 ± 2.14
  Proximal esophagus35.4 ± 3.79
Specific treatment received, n (%)
  Dietary elimination2 (2%)
  PPI38 (29%)
  STC59 (46%)
  PPI + STC30 (23%)

 

↓  Table 3. Demographic Characteristics of Patients Who Responded to Dupilumab
 
SD: standard deviation; PPI: proton pump inhibitor; STC: swallowed topical corticosteroid.
Age at diagnosis (1–17 years), mean ± SD8.91 ± 4.47
Sex, n (%)
  Male10 (63%)
  Female6 (37%)
Race
  White69%
  Black25%
  Hispanic6%
Comorbidities
  Atopic condition(s)75%
  None25%
Symptom severity
  Food impaction13%
  Prior esophageal dilation6%
Treatment(s) prior to dupilumab
  PPI and STC82%
  STC only18%
Number of failed treatment(s)
  Two treatments100%
Duration of previous treatment(s)3–12 months
Reason for discontinuation
  Inadequate response62%
  Intolerance25%
  Non-compliance13%